The Wockhardt Group, once a prominent player in the pharmaceutical industry, is facing severe difficulties. With mounting debts and a struggling business, the group's valuable assets are now headed to market. This sudden shift in fortunes has sent shockwaves through the industry, leaving many observers. It remains uncertain who will ultimately acq